168 related articles for article (PubMed ID: 24216547)
21. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials.
Assifi MM; Lu X; Eibl G; Reber HA; Li G; Hines OJ
Surgery; 2011 Sep; 150(3):466-73. PubMed ID: 21878232
[TBL] [Abstract][Full Text] [Related]
22. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study.
Aadam AA; Evans DB; Khan A; Oh Y; Dua K
Gastrointest Endosc; 2012 Jul; 76(1):67-75. PubMed ID: 22483859
[TBL] [Abstract][Full Text] [Related]
24. New developments in the management of borderline resectable pancreatic cancer.
Sharma J; Ng J; Goodman MD; Saif MW
JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.
Zhan HX; Xu JW; Wu D; Wu ZY; Wang L; Hu SY; Zhang GY
Cancer Med; 2017 Jun; 6(6):1201-1219. PubMed ID: 28544758
[TBL] [Abstract][Full Text] [Related]
26. Management of borderline resectable pancreatic adenocarcinoma.
Jia Y; Wang TJ; Allendorf J; Saif MW
JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
[TBL] [Abstract][Full Text] [Related]
27. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
Motoi F; Kawaguchi K; Aoki T; Kudo K; Yabuuchi S; Fukase K; Mizuma M; Sakata N; Otsutomo S; Morikawa T; Hayashi H; Nakagawa K; Okada T; Yoshida H; Naitoh T; Katayose Y; Egawa S; Unno M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1632-6. PubMed ID: 24393872
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
Unno M; Hata T; Motoi F
Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant/downstaging radiochemotherapy in marginally resectable pancreatic cancer.
Ansari D; Kervinen M; Andersson R
Hepatogastroenterology; 2014; 61(136):2387-90. PubMed ID: 25699388
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant strategy as initial treatment in resectable pancreatic cancer: concrete evidence of benefit.
DE Felice F; Musio D; Raffetto N; Tombolini V
Anticancer Res; 2014 Sep; 34(9):4673-6. PubMed ID: 25202043
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant treatment for resectable pancreatic cancer.
Chua YJ; Cunningham D
J Clin Oncol; 2005 Jul; 23(20):4532-7. PubMed ID: 16002844
[TBL] [Abstract][Full Text] [Related]
33. [Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy?].
Maurer CA; Zgraggen K; Büchler MW
Zentralbl Chir; 1999; 124(5):401-7. PubMed ID: 10420525
[TBL] [Abstract][Full Text] [Related]
34. New developments in the management of borderline resectable pancreatic cancers.
Goodman MD; McPartland S; Huber K; Saif MW
JOP; 2013 Jul; 14(4):334-6. PubMed ID: 23846921
[TBL] [Abstract][Full Text] [Related]
35. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study.
Parsonson AO; Connolly E; Lee M; Hruby G; Sandroussi C; Merrett N; Samra J; Mittal A; Tse R; Grimison P
ANZ J Surg; 2021 Nov; 91(11):2447-2452. PubMed ID: 34427029
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis.
D'Angelo F; Antolino L; Farcomeni A; Sirimarco D; Kazemi Nava A; De Siena M; Petrucciani N; Nigri G; Valabrega S; Aurello P; Ramacciato G
Med Oncol; 2017 May; 34(5):85. PubMed ID: 28391577
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant therapy in pancreatic cancer.
Quiros RM; Brown KM; Hoffman JP
Cancer Invest; 2007 Jun; 25(4):267-73. PubMed ID: 17612937
[TBL] [Abstract][Full Text] [Related]
38. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
40. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies.
Tomasello G; Ghidini M; Ghidini A; Trevisan F; Celotti A; Russo A; Gambini D; Indini A; Rijavec E; Bareggi C; Galassi B; Petrelli F
Radiother Oncol; 2021 Nov; 164():13-19. PubMed ID: 34509562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
